Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia

Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the...

Full description

Bibliographic Details

Main Authors:	How, Soon Hin, Chong, Kin Liam, Zainal Abidin, Muhammad 'Adil, Hasbullah, Harissa H, Lye, Mun Tho, Gwo, Fuang Ho, Muhamad Nor, Ibtisam, Yong, Kek Pang, Kean, Fatt Ho, Thiagarajan, Muthukkumaran, Ariffin, Roziana, Samsudin, Azlina, Omar, Azza, Sin, Nee Tan, Choo, Khoon Ong, Sing, Yang Soon, Mau, Ern Poh
Format:	Article
Language:	en
Published:	Dove Medical Press Ltd 2022
Subjects:	RC254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:	http://irep.iium.edu.my/98376/13/98376_Outcomes%20of%20patients%20with%20EGFR-mutant.pdf http://irep.iium.edu.my/98376/ https://www.dovepress.com/outcomes-of-patients-with-egfr-mutant-advanced-nsclc-in-a-developing-c-peer-reviewed-fulltext-article-CMAR
Tags:	Add Tag No Tags, Be the first to tag this record!